These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 9644121)

  • 21. Alarming epidemics of human immunodeficiency virus and hepatitis C virus among injection drug users in the northwestern bordering state of Punjab, India: prevalence and correlates.
    Panda S; Roy T; Pahari S; Mehraa J; Sharma N; Singh G; Singh J; Joseph F; Singh S; Sharma NM
    Int J STD AIDS; 2014 Jul; 25(8):596-606. PubMed ID: 24352120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users.
    Devi KhS; Singh NB; Singh HL; Singh YM
    J Indian Med Assoc; 2009 Mar; 107(3):144, 146-7. PubMed ID: 19810379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges.
    Hutchinson SJ; Roy KM; Wadd S; Bird SM; Taylor A; Anderson E; Shaw L; Codere G; Goldberg DJ
    Scott Med J; 2006 May; 51(2):8-15. PubMed ID: 16722130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-reported hepatitis C virus antibody status and risk behavior in young injectors.
    Hagan H; Campbell J; Thiede H; Strathdee S; Ouellet L; Kapadia F; Hudson S; Garfein RS
    Public Health Rep; 2006; 121(6):710-9. PubMed ID: 17278406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.
    Tun W; Vu L; Adebajo SB; Abiodun L; Sheehy M; Karlyn A; Njab J; Ahonsi B; Issa BK; Idogho O
    Int J STD AIDS; 2013 Aug; 24(8):619-25. PubMed ID: 23970571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.
    Rhodes T; Davis M; Judd A
    Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW).
    Salek TP; Katz AR; Lenze SM; Lusk HM; Li D; Des Jarlais DC
    Int J Drug Policy; 2017 Oct; 48():34-43. PubMed ID: 28779632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
    Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ;
    J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus among genitourinary clinic attenders in Scotland: unlinked anonymous testing.
    Goldberg D; Cameron S; Sharp G; Burns S; Scott G; Molyneaux P; Scoular A; Downie A; Taylor A
    Int J STD AIDS; 2001 Jan; 12(1):17-21. PubMed ID: 11177477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics.
    Balogun MA; Murphy N; Nunn S; Grant A; Andrews NJ; Teo CG; Ramsay ME; Parry JV
    Epidemiol Infect; 2009 Jul; 137(7):980-7. PubMed ID: 19102796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs.
    MacDonald MA; Wodak AD; Dolan KA; van Beek I; Cunningham PH; Kaldor JM
    Med J Aust; 2000 Jan; 172(2):57-61. PubMed ID: 10738473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
    Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
    Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland.
    Hutchinson SJ; Bird SM; Goldberg DJ
    Hepatology; 2005 Sep; 42(3):711-23. PubMed ID: 16116637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of anti-hepatitis C virus (anti-HCV) antibody and HCV-related risk in injecting drug users in northern India: comparison with non-injecting drug users.
    Basu D; Kumar V; Sharma AK; Barnwal PK; Mattoo SK
    Asian J Psychiatr; 2013 Feb; 6(1):52-5. PubMed ID: 23380318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus infection and related risk factors among injection drug users in Montenegro.
    Baćak V; Laušević D; Mugoša B; Vratnica Z; Terzić N
    Eur Addict Res; 2013; 19(2):68-73. PubMed ID: 23006531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan.
    Liu JY; Lin HH; Liu YC; Lee SS; Chen YL; Hung CC; Ko WC; Huang CK; Lai CH; Chen YS; Shih YL; Chung HC; Liang SH; Lin JN
    Clin Infect Dis; 2008 Jun; 46(11):1761-8. PubMed ID: 18433337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.
    McDonald SA; Hutchinson SJ; Cameron SO; Innes HA; McLeod A; Goldberg DJ
    Int J Drug Policy; 2012 Sep; 23(5):353-7. PubMed ID: 22421553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.